Alzheimer's disease (AD) is the most common major neurocognitive disorder of ageing.
Although largely ignored until about a decade ago, accumulating evidence suggests that …

There is growing evidence that ketone bodies, which are derived from fatty acid oxidation
and usually produced in fasting state or on high-fat diets have broad neuroprotective effects …

Background Multiple sclerosis (MS) is the most common inflammatory disease of the central
nervous system in young adults that may lead to progressive disability. Since …

The prevalence of obesity tripled worldwide between 1975 and 2016, and it is projected that
half of the US population will be overweight by 2030. The obesity pandemic is attributed, in …

We propose that brain energy deficit is an important pre-symptomatic feature of Alzheimer's
disease (AD) that requires closer attention in the development of AD therapeutics. Our …

INTRODUCTION The ketogenic diet (KD) is an intriguing therapeutic candidate for
Alzheimer's disease (AD) given its protective effects against metabolic dysregulation and …

Alzheimer's disease (AD) deaths have increased by 89% since 2000. This alarming
trajectory of neurological disease highlights the failure of current best practice. Deteriorating …

Ketogenic diets have a century-long history as a therapeutic tool to treat intractable epilepsy.
Recently, a renewed interest in neuroketotherapeutics has arisen, with ketogenic diets being …

Dementia is a growing public health concern, with an estimated prevalence of 57 million
adults worldwide. Alzheimer's disease (AD) accounts for 60–80% of the cases. Clinical trials …

Clinical and animal studies suggested that a medium-chain triglyceride (MCT)-based
ketogenic diet provides an alternative energy substrate to the brain and has neuroprotective …